EXAGEN INC.
Exagen is a medical technology company that develops and commercializes blood tests to help diagnose, assess prognosis and monitor complex rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Its AVISE® brand includes 10 commercialized tests, with AVISE® CTD as its flagship product. The portfolio also includes tests for antiphospholipid syndrome, vasculitis, lupus prognosis and monitoring, and monitoring medication levels. Exagen’s specialized laboratory provides testing services, primarily for rheumatologists, and its sales channel targets approximately 6,000 rheumatologists across the United States. It also offers AVISE® Anti-CarP through a distribution agreement with Werfen USA, LLC. Exagen makes money by providing its tests, with AVISE® CTD accounting for 91% of revenue for each of the years ended December 31, 2025 and 2024. The company is headquartered in Vista, California.
Exagen reported Q3 2026 revenue of $18.4M, up 7% YoY, with a net loss of $6.3M. Gross margin was 58.8%, and adjusted EBITDA loss was $1.9M. The company maintained its 2026 revenue guidance of $72M to $75M. AVISE CTD's average selling price rose to $451 per test, marking 14 consecutive quarters of growth.
EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio
Exagen Inc. (XGN) reported Q3 revenue of $18.4M, up 7% YoY, with year-to-date revenue growth of 11%. Net loss decreased 12% and adjusted EBITDA loss improved over 30%. The company reiterated its 2026 revenue guidance of $72M to $75M.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning XGN (EXAGEN INC.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 5 bearish.
Recent XGN coverage spans earnings, insider activity and corporate actions.
In the last 30 days, XGN insiders filed 2 SEC Form 4 transactions — 1 purchase ($104K) and 1 sale ($270K). The most active reporter was Chernett Jorey with 1 filing.
Earnings miss on profit margins and continued net loss; guidance unchanged.
Quarterly earnings release with modest revenue growth and reaffirmed guidance.
Revenue growth and narrowing losses may lift the stock modestly.
Small insider purchase may signal confidence but limited market impact.
The insider sale may signal personal liquidity needs or lack of confidence, potentially pressuring the stock.
AlphAI scores every news story that mentions XGN with an AI model for sentiment and relevance, and aggregates insider trades from EXAGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Exagen reported Q3 2026 revenue of $18.4M, up 7% YoY, with a net loss of $6.3M. Gross margin was 58.8%, and adjusted EBITDA loss was $1.9M. The company maintained its 2026 revenue guidance of $72M to $75M. AVISE CTD's average selling price rose to $451 per test, marking 14 consecutive quarters of growth.
EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio
Exagen Inc. (XGN) reported Q3 revenue of $18.4M, up 7% YoY, with year-to-date revenue growth of 11%. Net loss decreased 12% and adjusted EBITDA loss improved over 30%. The company reiterated its 2026 revenue guidance of $72M to $75M.
Chernett Jorey purchased 14,000 shares of EXAGEN INC. (XGN) at $7.46 ($0.10M total) on 2026-10-19.
ABALLI JOHN (President and CEO) sold 34,294 shares of EXAGEN INC. (XGN) at $7.87 ($0.27M total) on 2026-10-16.
Black Jeffrey G. (Chief Financial Officer) sold 20,614 shares of EXAGEN INC. (XGN) at $7.22 ($0.15M total) on 2026-09-01.
Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.
Exagen Inc. (Nasdaq: XGN) reported Q2 2026 results for the quarter ended June 30. Total revenue rose to $19.9 million, up 16% year over year, with AVISE CTD test volume up 11% and trailing twelve-month ASP at $446. Adjusted EBITDA loss narrowed to $0.1 million. Full-year 2026 revenue guidance increased to $72 to $75 million.
EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,
EXAGEN INC. (XGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. exdx-20260609 0001274737 FALSE 0001274737 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
